NCT00874471

Brief Summary

Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to:

  1. 1.Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis
  2. 2.Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's
  3. 3.Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits
  4. 4.Correlate the changes in gene expression with the prognosis of the ocular inflammatory process.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
280

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2005

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

April 1, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 2, 2009

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2010

Completed
Last Updated

April 9, 2014

Status Verified

April 1, 2014

Enrollment Period

5.1 years

First QC Date

April 1, 2009

Last Update Submit

April 7, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Correlation of blood transcriptome with form of uveitis

    time of office visit for disease evaluation

Study Arms (10)

sarcoidosis

ankylosing spondylitis

Behcet's disease

toxoplasmosis

herpetic acute retinal necrosis

idiopathic uveitis

ankylosing spondylitis (no uveitis)

sarcoidosis (no uveitis)

Behcet's disease (no uveitis)

normal control

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals suffering from selected subtypes of uveitis, individuals suffering from selected autoimmune disease and healthy individuals.

You may qualify if:

  • The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes:
  • ankylosing spondylitis
  • sarcoidosis
  • Behçet's disease
  • toxoplasmosis
  • herpetic acute retinal necrosis; AND
  • idiopathic uveitis
  • Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows:
  • ankylosing spondylitis
  • sarcoidosis; AND
  • Behçet's disease
  • The study group will also include 30 normal control volunteers aged 21 years or older.

You may not qualify if:

  • Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oregon Health & Science University

Portland, Oregon, 97239-3098, United States

Location

MeSH Terms

Conditions

Uveitis

Condition Hierarchy (Ancestors)

Uveal DiseasesEye Diseases

Study Officials

  • James Rosenbaum, MD

    Oregon Health and Science University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 1, 2009

First Posted

April 2, 2009

Study Start

June 1, 2005

Primary Completion

July 1, 2010

Last Updated

April 9, 2014

Record last verified: 2014-04

Locations